

Adult Congenital Heart Association

Webinars Presents:


Complementary/Alternative Medicine and Implications for ACHD

Monday, 10/23/2017, 7 p.m. – 8 p.m. EDT

Presenter: Karen Kuehl, MD, MPH

About the Webinar

Are you interested in learning more about the interactions of the body and mind in promoting your health? Do you want to know about techniques to decrease your levels of stress? If so, you don't want to miss this webinar. Dr. Karen Kuehl, ACHD cardiologist will talk about these techniques, as well as discuss study outcomes of mind body techniques in heart failure. Is the preliminary data enough?



REGISTER NOW: <http://bit.ly/2yc19Kh>

About the Presenter

Karen Kuehl, MD, MPH, is Emeritus Professor at George Washington University School of Medicine, Washington D.C. She is a graduate of Swarthmore College, Harvard Medical School and Johns Hopkins School of Public Health. She was the founder and first director of the Washington Adult Congenital Heart Program (WACH). She is trained in and certified by the Center for Mind Body Medicine in mind body medicine techniques. Her research interests now are focused on adaptation to chronic illness, with recognition of the etiology of medical post-traumatic stress disorder in people with many kinds of health experiences. Dr. Kuehl is an Emeritus Member of the ACHA Medical Advisory Board.

About the Adult Congenital Heart Association

The Adult Congenital Heart Association (ACHA) is a national not-for-profit organization dedicated to improving the quality of life and extending the lives of adults with congenital heart disease (CHD). ACHA serves and supports the more than one million adults with CHD, their families and the medical community—working with them to address the unmet needs of the long-term survivors of congenital heart defects through education, outreach, advocacy, and promotion of ACHD research. For more information about ACHA, contact (888) 921-ACHA or visit www.achaheart.org.

This webinar is made possible in part by unrestricted educational grants from Actelion Pharmaceuticals US, Gilead Sciences, Inc., and St. Jude Medical Foundation.